Dextenza is owned by Ocular Therapeutix.
Dextenza contains Dexamethasone.
Dextenza has a total of 4 drug patents out of which 0 drug patents have expired.
Dextenza was authorised for market use on 30 November, 2018.
Dextenza is available in insert;ophthalmic dosage forms.
Dextenza can be used as dextenza is approved for the treatment of ocular pain following ophthalmic surgery, treatment of ocular itching associated with allergic conjunctivitis; treatment of ocular inflammation and pain following ophthalmic surgery.
The generics of Dextenza are possible to be released after 16 November, 2037.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9254267||OCULAR THERAPEUTIX||Composite hydrogel drug delivery systems|| |
(1 year, 5 months from now)
|US8563027||OCULAR THERAPEUTIX||Drug delivery through hydrogel plugs|| |
(6 years from now)
|US8409606||OCULAR THERAPEUTIX||Drug delivery through hydrogel plugs|| |
(7 years from now)
|US11458041||OCULAR THERAPEUTIX||Punctal plug and bioadhesives|| |
(14 years from now)
|New Indication (I)||Oct 7, 2024|
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain following ophthalmic surgery
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic